Can filtering the blood slow ALS in patients with a rogue antibody?

NCT ID NCT05562960

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This trial investigates whether plasmapheresis — a procedure that filters the blood to remove harmful antibodies — can slow the progression of amyotrophic lateral sclerosis (ALS) in patients who have a specific autoantibody against a protein called NRIP. The study will enroll 5 adults with ALS who test positive for this antibody. Researchers will measure changes in motor function and breathing capacity before and after the treatment to see if removing the antibody makes a difference.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
plasmapheresis (a procedure that filters the blood to remove harmful antibodies)
What this could lead to
If effective, this could offer a treatment option for a small subset of ALS patients who carry the anti-NRIP autoantibody.
What could go wrong
This is a very small, early-stage trial with only 5 participants. It is unclear whether removing the antibody will meaningfully slow disease progression, and plasmapheresis carries risks such as infection or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Taiwan University Hospital

    Taipei, 100, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.